AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
+0.038 (4.56%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.83 - 0.90
52 week 0.80 - 3.50
Open 0.83
Vol / Avg. 81,139.00/290,073.00
Mkt cap 53.43M
P/E     -
Div/yield     -
EPS -0.41
Shares 58.18M
Beta 0.64
Inst. own 28%
Mar 4, 2016
Q4 2015 Aveo Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Feb 9, 2016
Aveo Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
Jan 13, 2016
Aveo Pharmaceuticals Inc at EBD Biotech Showcase - Webcast
Dec 21, 2015
AVEO Oncology and EUSA Pharma Announce Exclusive Licensing Agreement for Tivozanib In Renal Cancer - Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 52.21% -291.01%
Operating margin 55.86% -278.37%
EBITD margin - -179.34%
Return on average assets 81.69% -48.61%
Return on average equity 180.80% -116.49%
Employees 57 -
CDP Score - -


One Broadway, 14Th Floor
United States - Map
+1-617-5312130 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AVEO Pharmaceuticals, Inc. (AVEO) is a biopharmaceutical company. The Company's platform has delivered insights into cancer and related disease. The Company's Human Response Platform (HRP) provides insights into cancer and related disease biology and is leveraged in the discovery and clinical development of its therapeutic candidates. The Company's product candidates include AV203, Ficlatuzumab, Tivozanib and AV380. AV203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV380 is for treatment of cachexia. Tivozanib is a potent selective long halflife vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).

Officers and directors

Michael P. Bailey President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Keith S. Ehrlich CPA Chief Financial Officer
Age: 64
Bio & Compensation  - Reuters
Michael N. Needle M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Henri A. Termeer Lead Out Side Director
Age: 69
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 65
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Raju S. Kucherlapati Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert C. Young M.D. Independent Director
Age: 75
Bio & Compensation  - Reuters